Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared

被引：23

作者：

Chaudhuri, KR

Dhawan, V

机构：

[1] Kings Coll Hosp London, Reg Movement Disorders Unit, London, England

[2] Univ Hosp Lewisham, London, England

[3] Kings Coll London, Guys Kings & St Thomas Sch Biomed Med, London WC2R 2LS, England

[4] Cent Hosp Bremerhaven, Dept Neurol, Bremerhaven, Germany

来源：

MOVEMENT DISORDERS | 2004年 / 19卷 / 12期

关键词：

D O I：

10.1002/mds.20330

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：1522 / 1523

页数：2

共 8 条

[1]

Appiah-Kubi LS, 2003, J APPL RES, V3, P356

[2]

DHAWAN V, 2004, IN PRESS J NEUROL NE

[3] Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole [J].

Frucht, S ;

Rogers, JD ;

Greene, PE ;

Gordon, MF ;

Fahn, S .

NEUROLOGY, 1999, 52 (09) :1908-1910

[4]

Müller T, 2003, CLIN NEUROPHARMACOL, V26, P109

[5] New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance [J].

Rascol, O ;

Pathak, A ;

Bagheri, H ;

Montastruc, JL .

MOVEMENT DISORDERS, 2004, 19 (06) :611-613

[6]

Serratrice Jacques, 2002, Cardiol Rev, V10, P334, DOI 10.1097/00045415-200211000-00005

[7] Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide [J].

Van Camp, G ;

Flamez, A ;

Cosyns, B ;

Goldstein, J ;

Perdaens, C ;

Schoors, D .

NEUROLOGY, 2003, 61 (06) :859-861

[8] Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease [J].

Van Camp, G ;

Flamez, A ;

Cosyns, B ;

Weytjens, C ;

Muyldermans, L ;

Van Zandijcke, M ;

De Sutter, J ;

Santens, P ;

Decoodt, P ;

Moerman, C ;

Schoors, D .

LANCET, 2004, 363 (9416) :1179-1183

← 1 →